From USFDA
Zydus Pharmaceuticals Inc., a wholly owned subsidiary of Cadila Healthcare has received final approval from USFDA to market Minocycline Hydrochloride Extended Release Tablets in strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg. Zydus has also received the tentative approval for Minocycline Hydrochloride Extended Release Tablets, 55 mg, 65 mg and 115 mg.Minocycline Hydrochloride Extended Release Tablets are a tetracycline class drug, indicated to treat only inflammatory lesions of non nodular moderate to severe acne vulgaris in patients 12 year of age and older.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app